Chinese researchers have made what they claim is “a historic breakthrough” in the treatment of haemophilia, an inherited disorder that can cause unstoppable bleeding. They designed gene therapy drug BBM-H901 to treat haemophilia B and have found it to be safe and effective in preventing bleeding events a year after infusion. After 58 weeks of treatment, the average level of.
Hemophilia is an inherited genetic disorder that prevents blood from clotting. Individuals with the disorder are prone to excessive and sometimes spontaneous. 27.05.2022, Sputnik International
Clinical trial results of Belief BioMed s hemophilia B gene therapy drug candidate BBM-H901 published in The Lancet Haematology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ On December 30th, 2021, Belief BioMed Group (BBM) announced that it has successfully dosed the first subject in the registrational gene therapy.